Skip to content

LSD: all studies

Page 217 of 282: studies 2,161 to 2,170 of 2,816, newest first. Back to the LSD overview

Research

The Psychedelic Renaissance: a Convergence of Indigenous Knowledge and Science

July 1, 2021 Ronan Peck, Ronan Peck 12 citations

In recent times, psychedelics have come back into the public eye, mostly through scientific intrigue about their healing potential. In the past decade, hundreds of studies have been conducted to explore the possible benefits, or risks, that these substances could bring to people – and there is great potential being found. This is the psychedelic renaissance, and with this phenomenon in full...

DOI: 10.15760/honors.1171 (opens in new tab) Indigenous Phenomenon The renaissance Perception +2

Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample

Frontiers in Psychiatry June 29, 2021 Keri Mans, Hannes Kettner, David Erritzøe et al. 65 citations

In the last 15 years, psychedelic substances, such as LSD and psilocybin, have regained legitimacy in clinical research. In the general population as well as across various psychiatric populations, mental well-being has been found to significantly improve after a psychedelic experience. Mental well-being has large socioeconomic relevance, but it is a complex, multifaceted construct. In this...

DOI: 10.3389/fpsyt.2021.647909 (opens in new tab) Psilocybin Mental health Well-being Clinical psychology +3

Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders

Canadian Journal of Health Technologies June 24, 2021 Yi‐sheng Chao, Jennifer Horton 5 citations

Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations of psychedelic-assisted psychotherapy. Psilocybin was the psychedelic most tested. Other psychedelics identified in the systematic reviews and primary studies were 3,4-methylenedioxymethamphetamine (or MDMA), lysergic acid diethylamide (or LSD), ayahuasca...

Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

OBM Neurobiology June 24, 2021 Sarah-Catherine Rodan, Phillip Aouad, Iain S. Mcgregor et al. 10 citations

Anorexia Nervosa (AN) is a major health problem with one of the highest mortalities and treatment costs of any psychiatric condition. Cognitive behavioural therapy (CBT) is currently the most widely used treatment for AN in adults but provides remission rates ≤ 50%. Treatment drop-out is exceedingly high and those that persevere with treatment often relapse, causing increased risk of morbidity...

Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current Practice

Journal of Humanistic Psychology June 23, 2021 Elizabeth M. Nielson 26 citations

The therapeutic use of psilocybin in psychedelic-assisted therapy models is currently being tested for a variety of indications, necessitating the training of hundreds of therapists. At present, training programs do not include the provision of a psilocybin experience for therapists, and the last time such an experience was offered with a similar compound was through the Spring Grove LSD...

DOI: 10.1177/00221678211021204 (opens in new tab) Psilocybin Psychotherapist Training meteorology Consciousness +4

Silencing indigenous pasts: critical Indigenous theory and the history of psychedelics

International Journal of Qualitative Studies in Education June 21, 2021 Andrea Ens 21 citations

In this manuscript, I reflect on how Critical Indigenous theory offers white historians like myself powerful conceptual tools to combat the underlying, historically-rooted colonial assumptions prevalent in their work, specifically within the subfield of psychedelic history. Histories of compounds like lysergic acid diethylamide (LSD), psilocybin, ayahuasca, and mescaline often center themselves...

DOI: 10.1080/09518398.2021.1942297 (opens in new tab) Psilocybin Indigenous Cognitive reframing White mutation +6

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study

Frontiers in Psychiatry June 16, 2021 Dóra Révész, Genís Ona, Giordano Novak Rossi et al. 42 citations

Background: One of the main public health strategies adopted at the beginning of the COVID-19 pandemic consisted of implementing strict lockdowns to stop the transmission of the virus. Despite being an effective measure, the confinement and the associated social isolation create a stressful, potentially lengthy situations that has been proven to have several psychological consequences. Given...

Potencial terapéutico de los alucinógenos en las cefaleas: una revisión teórica

Escritos de Psicología / Psychological Writings June 15, 2021 Laura Collantes, José Francisco Navarro

Los alucinógenos incluyen a un grupo heterogéneo de sustancias que provocan cambios en la percepción sensorial, el pensamiento y la consciencia. El potencial terapéutico de diversas drogas alucinógenas está recibiendo un interés creciente en los últimos años. En este trabajo presentamos una revisión bibliográfica centrada en el posible uso de los alucinógenos (LSD, psilocibina y ketamina) en el...

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials

June 14, 2021 Luisa Prochazkova, Michiel van Elk, Josephine Marschall et al. 4 citations preprint

Introduction: Microdosing refers to the repetitive administration of tiny doses of psychedelics (LSD, Psilocybin) over an extended period of time. This practice has been linked to alleged cognitive benefits, such as improved mood and creativity, potentiated by targeting serotonergic 5-HT2A receptors and facilitating cognitive flexibility. Nonetheless, in the absence of robust, quantitative and...

Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.

Experimental and Clinical Psychopharmacology June 7, 2021 Colleen Fogg, Timothy I. Michaels, Sara de la Salle et al. 53 citations

Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use disorders, posttraumatic stress...

DOI: 10.1037/pha0000490 (opens in new tab) Psychotherapist Clinical psychology